-
Journal of Asthma and Allergy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Current recommendations for the treatment of mild asthma
Review
(3354) Views (758) Full article downloads
Authors: Neal Shahidi, J Mark FitzGerald
Published Date December 2010
Volume 2010:3 Pages 169 - 176
DOI: http://dx.doi.org/10.2147/JAA.S14420
Neal Shahidi, J Mark FitzGeraldDivision of Respiratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Abstract: Patients suffering from mild asthma are divided into intermittent or persistent classes based on frequency of symptoms and reliever medication usage. Although these terms are used as descriptors, it is important to recognize the approach of focusing on asthma control in managing asthma patients. Beta-agonists are considered first-line therapy for intermittent asthmatics. If frequent use of beta-agonists occurs more than twice a week, controller therapy should be considered. For persistent asthma, low-dose inhaled corticosteroids are recommended in addition to reliever medication. Compliance to regular therapy can pose problems for disease management, and while intermittent controller therapy regimens have been shown to be effective, it is imperative to stress the value of regular therapy especially if an exacerbation occurs. It is also important when such an approach is adopted that there is regular re-evaluations of asthma control. This is because regular anti-inflammatory therapy may become necessary if symptoms become more persistent. Other therapies are seldom needed. Antileukotrienes can be considered an option for mild asthma; however, studies have shown that they are not as effective as inhaled corticosteroids. Aside from therapy, patient education, which includes a written action plan, should be a component of the patient's strategy for disease management.
Keywords: mild asthma, treatment, inhaled corticosteroids, asthma education
Readers of this article also read:
Immunological and genetic aspects of asthma and allergy
The impact of asthma on the gastrointestinal tract (GIT)
Educational and behavioral interventions for asthma: who achieves which outcomes? A systematic review
New therapies and management strategies in the treatment of asthma: patient-focused developments
Update on optimal use of omalizumab in management of asthma
Clinical update on the use of biomarkers of airway inflammation in the management of asthma
Successful treatment of reactive airways dysfunction syndrome by high-dose vitamin D
The impact of vitamin D deficiency on immune T cells in asthmatic children: a case-control study
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions




